TransMedics Inc. drummed up $2.5 million from 13 unidentified investors in a debt offering, according to a filing with the federal Securities and Exchange Commission.
The Andover-based firm is developing a system to keep organs viable outside the body until they can be transplanted. It’s got CE Mark approval for sale in the European Union and is undergoing clinical trials for use in heart transplants in the U.S.
The debt sales is the latest round of financing for TransMedics, which says it’s raised $90 million in venture-capital backing.